Evaluation of the effect of the antiepiletic levetiracetum on seizure control and expression of MGMT in patients with gliomas (Phase II clinical trial)

Evaluation of the effect of the antiepiletic levetiracetum on seizure control and expression of MGMT in patients with gliomas (Phase II clinical trial) - LEV for Glioma

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017531

Enrollment

Registered

2015-05-14

Start date

2014-10-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

medication of levetiracetum

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with gliomas without history of radiotherapy or chemotherapy 2. Age >=20 3. ECOG PS=0,1,2 or 3 (by neurological deficit due to glioma) 4. Meet the criteria of blood test (neutrophil, Hb, Plt, AST, ALT. Total bilirubin, Serum Creatinine) 5. Written informed consent

Exclusion criteria

Exclusion criteria: 1. History of allergy to the ingredients of levetiracetum or pyrrolidones 2. History of status epilepticus or intractable epilepsy 3. Serious psychotic disorder 4. Pregnant or breast feeding women 5. Severe heart disease, or liver dysfunction, or renal dysfunction

Design outcomes

Primary

Measure	Time frame
6-months retention rate of LEV	—

Secondary

Measure	Time frame
Expression of MGMT (by immunohistochemistry)	—

Countries

Japan

Contacts

Public ContactYuko Tatsuno

Keio University School of Medicine Neurosurgery

tatsunoy@a6.keio.jp03-5363-3808

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026